

FOR IMMEDIATE RELEASE:

ImmuCell Appoints Elizabeth Williams Vice President of Manufacturing Operations

Contact: Michael F. Brigham, President and CEO
ImmuCell Corporation
(207) 878-2770

Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
(602) 889-9700
iccc@lythampartners.com

PORTLAND, Maine – April 4, 2016 – **ImmuCell Corporation (NASDAQ: ICCC)**, a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced the hiring of Ms. Elizabeth L. Williams as Vice President of Manufacturing Operations.

Elizabeth Williams brings extensive experience from a successful career with Zoetis and Pfizer Animal Health in a broad range of leadership roles including quality, validation, process and product development, manufacturing and site leadership at multiple locations. Most recently, she led the U.S. Region for Zoetis as Vice President, Global Manufacturing and Supply. Her breadth of expertise includes building and expanding biopharmaceutical facilities, qualifying and launching new products and processes, and leading the manufacturing and support functions at sites regulated by the USDA, FDA and other international regulatory authorities. She earned her Masters of Business Administration from Rockhurst University in Kansas City, Missouri and her Bachelor's degree in Biology from the University of Missouri.

“Having Elizabeth Williams join us at this critical point in our expansion is an important milestone and essential to our successful growth going forward,” commented Michael F. Brigham, President and Chief Executive Officer. “Betsy brings a depth of experience that will have an immediate impact on our **First Defense**[®] operations, as we increase production capacity to meet increasing sales demand and prepare to bring a new trivalent claim for this product to market. Most importantly, she will lead the construction and installation of our commercial-scale production facility for **Mast Out**[®].”

“I am very excited about the opportunity to have an immediate and measurable impact on the strong revenue growth at ImmuCell,” commented Ms. Williams. “I have been impressed by what ImmuCell has achieved and am eager to be part of the team expanding production of **First Defense**[®] and completing the development of the **Mast Out**[®] facilities and processes through to FDA approval and subsequent commercialization.”

About ImmuCell

ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that improve animal health and productivity in the dairy and beef industries. ImmuCell has developed products that provide significant, immediate immunity to newborn dairy and beef livestock. The Company has also developed products that address mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at: (<http://www.immucell.com>).

Safe Harbor Statement:

*This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: projections of future financial performance; the scope and timing of future product development work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical mastitis; future market share of and revenue generated by products still in development; future sources of financial support for our product development, manufacturing and marketing efforts; the future adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the amount and timing of future investments in facility modifications and production equipment; the future adequacy of our working capital and the availability of third party financing; timing and future costs of a facility to produce the Drug Substance (active pharmaceutical ingredient) for **Mast Out**[®]; the timing and outcome of pending or anticipated applications for future regulatory approvals; future regulatory requirements relating to our products; future expense ratios and margins; future compliance with bank debt covenants; future realization of deferred tax assets; costs associated with sustaining compliance with cGMP regulations in our current operations and attaining such compliance for the facility to produce the Drug Substance for **Mast Out**[®]; factors that may affect the dairy and beef industries and future demand for our products; the cost-effectiveness of additional sales and marketing expenditures and resources; the accuracy of our understanding of our distributors' ordering patterns; anticipated changes in our manufacturing capabilities and efficiencies; anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts" and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, alignment between our manufacturing resources and product demand, the uncertainties associated with product development and Drug Substance manufacturing, our potential reliance*

upon third parties for financial support, products and services, changes in laws and regulations, decision making by regulatory authorities, possible dilutive impacts on existing stockholders from any equity financing transactions in which we may engage, currency fluctuations and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements are based on our current expectations, but actual results may differ materially due to various factors, including the risk factors summarized in our quarterly filings with the SEC and uncertainties otherwise referred to in this press release.